Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 Biomarker disease BEFREE This includes frequently reported gene fusions such as CCDC6/RET (PTC1), PRKAR1A/RET (PTC2) and ETV6/NTRK3 , and gene fusions that are less common in thyroid cancer (TPM3/NTRK1, EML4/ALK and EML4/NTRK3). 30668525 2019
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 Biomarker disease BEFREE Several drugs targeting RET have been approved by the FDA for the treatment of cancer: (i) cabozantinib and vandetanib for medullary thyroid carcinomas and (ii) lenvatinib and sorafenib for differentiated thyroid cancers. 29284153 2018
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 GeneticVariation disease BEFREE RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases. 29515777 2018
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 GeneticVariation disease BEFREE In the present study, we investigated whether the oncogenic RET mutants RET2A (C634R) and RET2B (M918T) were regulated by LRIG1, and the possible effects of LRIG1 expression in thyroid cancer were investigated in three different clinical cohorts and in a RET2B-driven mouse model of MTC. 29436694 2018
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 Biomarker disease BEFREE Several multikinase inhibitors with activity against RET have been explored in the clinic, and confirmed responses to targeted therapy with these agents have been observed in patients with RET-rearranged lung cancers or RET-mutant thyroid cancers. 29134959 2018
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 Biomarker disease BEFREE These results confirm that PATZ1 downregulation has a critical role in thyroid carcinogenesis, showing that it cooperates with RET/PTC1 in thyroid cancer progression. 29584698 2018
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 GeneticVariation disease BEFREE <i>In vivo</i>, BLU-667 potently inhibited growth of NSCLC and thyroid cancer xenografts driven by various <i>RET</i> mutations and fusions without inhibiting VEGFR2. 29657135 2018
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 Biomarker disease BEFREE While RET TK inhibitors (TKIs) are used to treat thyroid cancer and are in clinical trials for RET fusion-positive non-small cell lung cancer, the impact of mutations in the RET kinase domain on drug sensitivity is largely uncharacterized. 29908090 2018
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 Biomarker disease BEFREE The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer. 28911727 2017
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 Biomarker disease BEFREE Identification of Three Novel Fusion Oncogenes, SQSTM1/NTRK3, AFAP1L2/RET, and PPFIBP2/RET, in Thyroid Cancers of Young Patients in Fukushima. 28351223 2017
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 Biomarker disease BEFREE To assess the therapeutic potential of AL3810 in treating thyroid cancer involving RET gene fusion, we showed that AL3810 (1-10 μmol/L) dose-dependently inhibited the proliferation of RET-driven Baf3 cell line Baf3-CCDC6-RET, and the auto-phosphorylation of RET in these cells. 28795691 2017
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 Biomarker disease BEFREE Effect of Interferon-γ on the Basal and the TNFα-Stimulated Secretion of CXCL8 in Thyroid Cancer Cell Lines Bearing Either the RET/PTC Rearrangement Or the BRAF V600e Mutation. 27555670 2016
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 GeneticVariation disease BEFREE We evaluated the best tagging SNPs from our previous PTC study and additionally included SNPs in or near FOXE1 and NKX2-1 genes, known susceptibility loci for thyroid cancer. 27207655 2016
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 GeneticVariation disease BEFREE Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer. 27712045 2016
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 Biomarker disease BEFREE This substance also significantly suppresses growth of thyroid cancer-derived TT cell lines and Ba/F3 cells transformed with various RET mutants. 26652860 2016
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 Biomarker disease BEFREE RET, BRAF and other protein kinases have been identified as major molecular players in thyroid cancer. 27058903 2016
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 GeneticVariation disease BEFREE In present result, RET rs1799939, rs1800858 and rs74799832 polymorphisms might be the risk factors for TC. 26191299 2015
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 AlteredExpression disease BEFREE Here, we firstly find CNTN1 is a new gene which can be regulated by RET/PTC3 (Ret proto-oncogene and Ret-activating protein ELE1) rearrangement gene and the protein level of CNTN1 is increasing in thyroid cancer. 26722434 2015
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 GeneticVariation disease BEFREE Twenty-four (27%) of 89 patients were diagnosed with thyroid cancer (50% papillary thyroid carcinoma [PTC], 50% follicular variant of papillary thyroid carcinoma [FVPTC]). 25627462 2015
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 GeneticVariation disease BEFREE In particular, activating mutations of BRAF, RET or RAS genes are known to be specifically associated with TC initiation, progression and outcome. 25862858 2015
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 GeneticVariation disease BEFREE BRAF(V600E) mutation analysis is superior to RAS point mutations and evaluation of RET/PTC rearrangements in the diagnosis of thyroid cancer, even in indeterminate lesions. 25333496 2015
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 Biomarker disease BEFREE Rearranged during transfection (RET)/papillary thyroid carcinoma gene rearrangements, BRAF (B-RAF proto-oncogene, serine/threonine kinase) gene mutations, RAS (rat sarcoma) mutations, and vascular endothelial growth factor receptor 2 angiogenesis pathways are some of the known pathways playing a crucial role in the development of thyroid cancer. 25789503 2015
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 Biomarker disease BEFREE Our data indicate that RAF-1 is important for the survival of TPC-1 cells independently of the classical MEK1/2-ERK activation, offering new perspectives on RET/PTC signaling and for the therapy of thyroid cancers. 26265449 2015
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 GeneticVariation disease BEFREE Possible Impact of RET Polymorphism and Its Haplotypic Association Modulates the Susceptibility to Thyroid Cancer. 25736215 2015
Entrez Id: 5979
Gene Symbol: RET
RET
0.400 Biomarker disease BEFREE We sought to evaluate the prognostic value of the three most common genetic mutations (BRAF, RAS, and RET) in patients with thyroid cancer. 25244593 2015